Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study

Aaron Rosenberg, Cristiana Costa, Nirav Shah, Ahmad Mattour, Eudardo Miranda, Jing-Zhou Hou, Chuansheng Ge, Qiaoyun Yu, Juanjuan Wang, Huaping Wei, Lizhi Zhao, Yao Wang

Blood (2025) 146 (Supplement 1): 5809.

https://doi.org/10.1182/blood-2025-5809

Published: 2025

Journal Articles

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Blood (2025) 146 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2025-2115

Published: 2025

Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Nirav Shah, Scott Huntington, David Lewis, Talha Munir, Graham Collins, Alvaro Alencar, Kim Linton, Zulfa Omer, Dima El-Sharkawi, Mary Gleeson, Pamela McKay, Jeanette Doorduijn, Jeffery Smith, Daniel Morillo, Pau Abrisqueta, Sarah Injac, Astrid Pulles

Blood (2025) 146 (Supplement 1): 5359.

https://doi.org/10.1182/blood-2025-5359

Published: 2025

Journal Articles

Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study

Christopher Fletcher, Aniko Szabo, Sumana Devata, Vaishalee Kenkre, Priyanka Pophali, Luke Zurbriggen, Julie Chang, Katina Deshong, Mitch Howard, Mariah Endres, Joel Pollen, Esta Konkol, Walter Longo, Mehdi Hamadani, Timothy Fenske, Saurabh Rajguru, Nirav Shah

Blood (2025) 146 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2025-1964

Published: 2025

Journal Articles

Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL

Blood (2025) 146 (Supplement 1): 781.

https://doi.org/10.1182/blood-2025-781

Published: 2025

Journal Articles

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Blood (2025) 146 (Supplement 1): 669.

https://doi.org/10.1182/blood-2025-669

Published: 2025

Journal Articles

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Blood (2025) 146 (Supplement 1): 667.

https://doi.org/10.1182/blood-2025-667

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium

Blood (2025) 146 (Supplement 1): 398.

https://doi.org/10.1182/blood-2025-398

Published: 2025

Journal Articles

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Nitin Jain, Catherine Coombs, James D'Olimpio, Nirav Shah, Jacqueline Barrientos, Seung Tae Lee, Danielle Brander, John Nemunaitis, Andrew Gillis-Smith, Shuo Ma, Shirou Kirita, Koji Yoshida, Masaaki Sawa, Kyoko Miyamoto, Akinori Arimura, William Wierda, Varsha Gandhi, Javier Pinilla-Ibarz

Blood (2025) 146 (Supplement 1): 3892.

https://doi.org/10.1182/blood-2025-3892

Published: 2025

Journal Articles

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 4502.

https://doi.org/10.1182/blood-2025-4502

Published: 2025

Journal Articles

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

Blood (2025) 146 (Supplement 1): 86.

https://doi.org/10.1182/blood-2025-86

Published: 2025

Journal Articles

CAR-T with ICOS costimulation lacks therapeutic efficacy in patient due to strong trogocytosis and failure of expansion

Yongxia Wu, Allison Pugel, Katie Palen, Peiman Hematti, Tyce Kearl, Rimas Orentas, Timothy Fenske, Mehdi Hamadani, Walter Longo, Bryon Johnson, Nirav Shah, Xue-Zhong Yu

Blood (2025) 146 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2025-2346

Published: 2025

Journal Articles

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

Nilanjan Ghosh, Julio Chavez, Mariana Bastos-Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam Olszewski, Seema Naik, Song Pham, Michael C. Wei, Connie L. Batlevi, Iris To, Wahib S. Ead, Sneha Makadia, Elicia Peneul, Elizabeth Budde

Blood (2025) 146 (Supplement 1): 1020.

https://doi.org/10.1182/blood-2025-1020

Published: 2025

Journal Articles

Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes

Adam Kidwell, Karolina Lungova, Aniko Szabo, Emilie Aschenbrenner, Timothy Schieber, Forat Lutfi, Wilder Widman, Austin Quick, Ashley Dunton, Bhagirathbhai Dholaria, Olalekan Oluwole, Rita Ahmad, Seth Maliske, Caitlin Guzowski, Scott Solomon, Melissa Babcook, Nathan Denlinger, Nirav Shah

Blood (2025) 146 (Supplement 1): 6302.

https://doi.org/10.1182/blood-2025-6302

Published: 2025

Journal Articles

Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians

Blood (2025) 146 (Supplement 1): 3746.

https://doi.org/10.1182/blood-2025-3746

Published: 2025

Journal Articles

The predictive value of the interleukin 2 receptor (IL2)/ferritin ratio in the diagnosis of lymphoma associated hemophagocytic lymphohistiocytosis (LAHS): A United States, multi center experience

Dariusz Uczkowski, Linzi Hobbs-Parker, Stephanie Yohay, Adarsh Ettyreddy, Natalia Gontarczyk Uczkowski, Chenyu Lin, Alexander Coltoff, Laura Michaelis, Lisa Baumann Kreuziger, Nirav Shah, Ehab Atallah

Blood (2025) 146 (Supplement 1): 4769.

https://doi.org/10.1182/blood-2025-4769

Published: 2025

Journal Articles

Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy

Blood (2025) 146 (Supplement 1): 4551.

https://doi.org/10.1182/blood-2025-4551

Published: 2025

Journal Articles

Phase II, single-arm, open-label, multicenter study: Efficacy of adjunctive Bruton's tyrosine kinase inhibitor (BTKi) zanubrutinib and chimeric antigen receptor (CART) in aggressive B-cell non-hodgkins lymphoma (aNHL)

Reem Karmali, Carlos Galvez, Jane Winter, Shuo Ma, Bin Zhang, Ping Xie, Yangruijue (Anna) Ma, Ruohui Chen, Nirav Shah, Leo Gordon

Blood (2025) 146 (Supplement 1): 1010.

https://doi.org/10.1182/blood-2025-1010

Published: 2025

Journal Articles

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

Blood (2025) 146 (Supplement 1): 960.

https://doi.org/10.1182/blood-2025-960

Published: 2025

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Kpg-818, a novel cereblon (CRBN) modulator, in patients with hematological malignancies: Results of a Phase 1, open-label, multiple ascending dose study

Pirtobrutinib in post-cbtki CLL/SLL: Final update from the Phase 1/2 BRUIN study with more than 5 years follow-up

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in patients with Waldenström macroglobulinemia: Updated results from an ongoing Phase 1a/b study

Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study

Real world comparison of commercial CAR T-cell constructs for the treatment of LBCL

Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study.

Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Impact of sequencing of CART vs bi-specific antibody on survival in relapsed/refractory large B-cell lymphoma: An analysis from the ABC consortium

Docirbrutinib (AS-1763), a novel non-COVALENT pan-mutant BTK inhibitor, demonstrates durable clinical responses in patients with previously treated B-cell malignancies: Data from an ongoing Phase 1b study

Bispecific antibody vs non-bispecific antibody systemic therapy as immediate next line treatment after chimeric antigen receptor T-cell (CART) failure in large B-cell lymphoma

Bexobrutideg (NX-5948), a novel Bruton's tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in Relapsed/Refractory chronic lymphocytic leukemia (CLL): New and updated findings from an ongoing Phase 1a/b trial

CAR-T with ICOS costimulation lacks therapeutic efficacy in patient due to strong trogocytosis and failure of expansion

Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma

Intrathecal chemotherapy for management of immune effector cell-associated neurotoxicity syndrome (ICANS): A multi-center, real-world analysis of clinical outcomes

Real-world outcomes with bispecific antibody therapies for aggressive B-cell lymphomas in octogenarians

The predictive value of the interleukin 2 receptor (IL2)/ferritin ratio in the diagnosis of lymphoma associated hemophagocytic lymphohistiocytosis (LAHS): A United States, multi center experience

Outcomes of patients with Relapsed/Refractory aggressive B-cell lymphoma receiving bispecific antibody therapy as monotherapy or in combination with targeted therapy

Phase II, single-arm, open-label, multicenter study: Efficacy of adjunctive Bruton's tyrosine kinase inhibitor (BTKi) zanubrutinib and chimeric antigen receptor (CART) in aggressive B-cell non-hodgkins lymphoma (aNHL)

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only